Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Jinhai Medical Technology's Enterprise Value is HK$31,854.6 Mil.
Jinhai Medical Technology's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-53.7 Mil. Therefore, Jinhai Medical Technology's EV-to-EBIT ratio for today is -592.75.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Jinhai Medical Technology (HKSE:02225) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Jinhai Medical Technology's EV-to-EBIT for today is
Jinhai Medical Technology's current Enterprise Value is HK$31,854.6 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Jinhai Medical Technology's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-53.7 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Jinhai Medical Technology's EV-to-EBITDA for today is:
Jinhai Medical Technology's current Enterprise Value is HK$31,854.6 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Jinhai Medical Technology's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-53.7 Mil.
Jinhai Medical Technology's current Enterprise Value is HK$31,854.6 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Jinhai Medical Technology's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was HK$398.4 Mil.
Jinhai Medical Technology's current Enterprise Value is HK$31,854.6 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Jinhai Medical Technology's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-34.4 Mil.
Jinhai Medical Technology's current Enterprise Value is HK$31,854.6 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Jinhai Medical Technology's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-34.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jinhai Medical Technology Enterprise Value Related Terms
Jinhai Medical Technology Enterprise Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02225 vs RHI, KFY, TNET: Enterprise Value Comparison
For the Conglomerates subindustry, Jinhai Medical Technology's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jinhai Medical Technology Enterprise Value vs Conglomerates Industry
For the Conglomerates industry and Industrials sector, Jinhai Medical Technology's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Jinhai Medical Technology's Enterprise Value falls into.
Jinhai Medical Technology Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Jinhai Medical Technology's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of HK$31,854.6 Mil mean?
Jinhai Medical Technology (HKSE:02225) has a Enterprise Value of HK$31,854.6 Mil as of Sep. 11, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Jinhai Medical Technology and its competitors.
Is Jinhai Medical Technology's Enterprise Value too high?
Jinhai Medical Technology's current Enterprise Value is HK$31,854.6 Mil. Overall, Jinhai Medical Technology has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jinhai Medical Technology's Enterprise Value compare to RHI and KFY?
Jinhai Medical Technology's Enterprise Value of HK$31,854.6 Mil can be compared against companies in the Conglomerates industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Conglomerates company?
A good Enterprise Value depends on the Conglomerates industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Jinhai Medical Technology and its competitors. Jinhai Medical Technology's current Enterprise Value is HK$31,854.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jinhai Medical Technology stock overvalued right now?
Based on GuruFocus' analysis, Jinhai Medical Technology (HKSE:02225) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$1.41, compared to a current price of HK$6.07 — trading 330.5% above its estimated fair value. The current Enterprise Value is HK$31,854.6 Mil. Jinhai Medical Technology's overall GF Score™ is 61/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Jinhai Medical Technology (HKSE:02225), the current Enterprise Value is HK$31,854.6 Mil as of Sep. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jinhai Medical Technology (HKSE:02225) Overvalued in 2026?
Based on GuruFocus' analysis, Jinhai Medical Technology stock appears to be overvalued.
The current stock price of HK$6.07 is trading 330.5% above its estimated GF Value™ of HK$1.41.
GuruFocus considers Jinhai Medical Technology to be Significantly Overvalued.
Key valuation signals for HKSE:02225:
Enterprise Value: HK$31,854.6 Mil
GF Value™: HK$1.41 vs. price of HK$6.07 (330.5% above fair value)
No single metric tells the full story. See the HKSE:02225 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jinhai Medical Technology Ltd is an investment holding company. Along with its subsidiaries, it is principally engaged in providing medical equipment in China and manpower outsourcing and ancillary services to building and construction contractors in Singapore. The group also provides IT services, construction ancillary services (which comprise warehousing, cleaning, and building maintenance works), and dormitory services in Singapore. It generates maximum revenue from the sale of minimally invasive surgery solutions, medical products, and related services in the People's Republic of China.
61GF Score
Get the complete analysis for HKSE:02225
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02225 has been successfully added to your 
